Your browser doesn't support javascript.
loading
Parenteral high­dose ascorbate - A possible approach for the treatment of glioblastoma (Review).
Renner, Olga; Burkard, Markus; Michels, Holger; Vollbracht, Claudia; Sinnberg, Tobias; Venturelli, Sascha.
Afiliación
  • Renner O; Department of Nutritional Biochemistry, University of Hohenheim, D­70599 Stuttgart, Germany.
  • Burkard M; Department of Nutritional Biochemistry, University of Hohenheim, D­70599 Stuttgart, Germany.
  • Michels H; Pascoe Pharmazeutische Praeparate GmbH, D­35394 Giessen, Germany.
  • Vollbracht C; Pascoe Pharmazeutische Praeparate GmbH, D­35394 Giessen, Germany.
  • Sinnberg T; Department of Dermatology, University Hospital Tuebingen, D­72076 Tuebingen, Germany.
  • Venturelli S; Department of Nutritional Biochemistry, University of Hohenheim, D­70599 Stuttgart, Germany.
Int J Oncol ; 58(6)2021 Jun.
Article en En | MEDLINE | ID: mdl-33955499
For glioblastoma, the treatment with standard of care therapy comprising resection, radiation, and temozolomide results in overall survival of approximately 14-18 months after initial diagnosis. Even though several new therapy approaches are under investigation, it is difficult to achieve life prolongation and/or improvement of patient's quality of life. The aggressiveness and progression of glioblastoma is initially orchestrated by the biological complexity of its genetic phenotype and ability to respond to cancer therapy via changing its molecular patterns, thereby developing resistance. Recent clinical studies of pharmacological ascorbate have demonstrated its safety and potential efficacy in different cancer entities regarding patient's quality of life and prolongation of survival. In this review article, the actual glioblastoma treatment possibilities are summarized, the evidence for pharmacological ascorbate in glioblastoma treatment is examined and questions are posed to identify current gaps of knowledge regarding accessibility of ascorbate to the tumor area. Experiments with glioblastoma cell lines and tumor xenografts have demonstrated that high­dose ascorbate induces cytotoxicity and oxidative stress largely selectively in malignant cells compared to normal cells suggesting ascorbate as a potential therapeutic agent. Further investigations in larger cohorts and randomized placebo­controlled trials should be performed to confirm these findings as well as to improve delivery strategies to the brain, through the inherent barriers and ultimately to the malignant cells.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ácido Ascórbico / Neoplasias Encefálicas / Glioblastoma Tipo de estudio: Clinical_trials / Prognostic_studies Aspecto: Patient_preference Límite: Animals / Humans Idioma: En Revista: Int J Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Grecia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ácido Ascórbico / Neoplasias Encefálicas / Glioblastoma Tipo de estudio: Clinical_trials / Prognostic_studies Aspecto: Patient_preference Límite: Animals / Humans Idioma: En Revista: Int J Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Grecia